aoc 1044
Gene therapyexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2022 (NCT05670730)
Timeline
Indications
Mechanism of action
- Dystrophin pre-mRNASupplementation
Dystrophin pre-mRNA supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068231 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06244082 | Phase 2 | Jan 22, 2024 | Avidity Biosciences, Inc. |
| NCT05670730 | Phase 1/Phase 2 (Phase 2) | Nov 9, 2022 | Avidity Biosciences, Inc. |
| NCT07250737 | N/A | — | Avidity Biosciences, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1